Latest News
Bio-Thera Solutions reports first patient dosed in Phase 1 study of BAT8013
24 July 2026 - Commercial-stage pharmaceutical company Bio-Thera Solutions Ltd (SH:688177) announced on Thursday that dosing has begun in a Phase 1 clinical study evaluating BAT8013, an antibody drug conjugate (ADC) that targets CD25.The multicentre,...
EU approves AstraZeneca's Etcamah combination for 1st-line ER-positive advanced breast cancer
23 July 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) announced on Thursday it has secured European Union approval for Etcamah (camizestrant) combined with a CDK4/6 inhibitor for adults with ER-positive, HER2-negati...
BeOne Medicines expands US manufacturing with USD300m investment
23 July 2026 - Oncology company BeOne Medicines Ltd (NASDAQ:ONC) (HKEX:06160) (SSE:688235) announced on Thursday that it will invest USD300m to expand its flagship manufacturing and research and development campus in Hopewell, New Jersey, increasing ...
FDA grants Fast Track designation to Lundbeck's narcolepsy candidate Lu AH69593
23 July 2026 - Danish biopharmaceutical company H. Lundbeck A/S (CPH: HLUN-B), which focuses on brain health, said on Thursday it has received Fast Track designation from the US Food and Drug Administration for Lu AH69593, its lead oral orexin 2 rece...
ABL Diagnostics selected to acquire TEXCELL operations
23 July 2026 - ABL Diagnostics (Euronext Paris:ABLD), a provider of molecular biology tests, announced on Thursday that it has been selected by the Évry Commercial Court to acquire the assets and business operations of TEXCELL, supporting the ...